1 Souhrn údajů o přípravku Velphoro®
2 Wilhelm M, Gaillard S, Rakov V, Funk F. The iron-based phosphate binder PA21 has potent phosphate binding capacity and minimal iron release across a physiological pH range in vitro. Clin Nephrol. 2014;81(4):251-258.
3 Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. New Engl J Med. 2010;362:1312-1324
4 Floege J et al., Safety and efficacy of PA21, a novel iron-based phosphate binder, in a long term phase III study. Floege J et al., Long-term effects of iron-based phosphate binder, sucroferric hydroxide, in dialysis patients. Nephrol Dial Transplant (2015) 0:1-9
5 De Francisco ALM et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) comparing efficacy and tolerability. Nephrol Dial Transplant 2010: DOI 10.1093/ndt/gfq292.
6 Souhrn údajů o přípravku Recisal®
7 Cook JD, Shikne BS. Iron deficiency: Definition and diagnosis. J Intern Med, 1989, 226, p. 349–355.
8 Fishbane S, Maesaka JK. Iron Management in End-Stage Renal Disease. Am J Kidney Dis, 1997
9 Major A et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. British Journal of Haematology 1997; 98: 292-294
10 Bailie GR et al. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443-1449
11 Data on file. Iron Sucrose Periodic Safety Update Report, February 2016. Luitpold Pharmaceuticals, Inc. Shirley, NY
12 Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38.
13 Lund RJ et al., Am J Nephrol 2010;31:165 -170
14 Sprague SM et al., Kidney Int 2003;63:1483 -1490
15 Mittman N et al., Kidney Int 2010;78 Suppl 117:33 – 36